Alkylating agents: all 3,295 studies that test it
Page 21 of 33. Open to participants first (456), then studies with results posted, then the rest; newest registration first within each.
- Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) PatientsActive, not recruitingNCT02499367Phase 2
- Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid TumorsActive, not recruitingNCT02498912Phase 1
- In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaWithdrawnNCT02489266Phase 1
- Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT MethylationTerminatedNCT02477813Phase 2
- Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings SarcomaCompletedNCT02472392Phase 1
- Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old PatientCompletedNCT02467946Phase 1/2
- Relapse Myeloma; Cyclofosfamide; Bortezomib; MaintenanceCompletedNCT02467010Phase 2
- Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic CancerTerminatedNCT02465983Phase 1
- Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary FibrosisCompletedNCT02460588Phase 3
- Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell MalignanciesStatus unknownNCT02456350Phase 1
- Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the PancreasActive, not recruitingNCT02451982Phase 2
- Adjuvant FEC Versus EP in Breast Cancer (MIG5)CompletedNCT02450058Phase 3
- Allogeneic Stem Cell Transplantation for Patients With Multiple MyelomaWithdrawnNCT02447055Early Phase 1
- Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute LeukemiaCompletedNCT02446964Phase 1
- Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior ChemotherapyStatus unknownNCT02446704Phase 1/2
- Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCLStatus unknownNCT02445404Phase 2
- Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLETerminatedNCT02444728Phase 3
- Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)CompletedNCT02444091Phase 2
- Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )WithdrawnNCT02441491Not applicable
- Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer PatientsWithdrawnNCT02441270Early Phase 1
- 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMAWithdrawnNCT02439788Phase 1
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaActive, not recruitingNCT02436707Phase 2
- Phase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerCompletedNCT02423928Phase 1
- Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular LymphomaStatus unknownNCT02423837Phase 3
- Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)WithdrawnNCT02419170Early Phase 1
- Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade GliomasStatus unknownNCT02416999Not applicable
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaTerminatedNCT02415036Phase 2
- TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma PatientsCompletedNCT02414945Phase 1/2
- Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and DoxorubicinCompletedNCT02414568Phase 2
- Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer PatientsCompletedNCT02414009Phase 2
- Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)WithdrawnNCT02408042Phase 1/2
- BNHL-2015 for Children or Adolescents in ChinaActive, not recruitingNCT02405676Phase 2/3
- Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid MalignanciesCompletedNCT02392793Phase 1
- Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS TumorsCompletedNCT02390843Phase 1
- Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid CancerWithdrawnNCT02390739Phase 1/2
- A Pharmacokinetic Study of Melphalan in ChildrenCompletedNCT02390544Phase 1
- Vaccination in Prostate Cancer (VANCE)CompletedNCT02390063Phase 1
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid TumorsActive, not recruitingNCT02389309Phase 1
- Bleb Function and Morphology With Intratendon Injection of MMC Compared With Standard MethodStatus unknownNCT02385370Phase 3
- Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain MetastasesStatus unknownNCT02385136Phase 1/2
- HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIACompletedNCT02379520Phase 1
- Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast CancerCompletedNCT02365805Phase 2
- CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple MyelomaStatus unknownNCT02362165Phase 3
- Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours StudyCompletedNCT02358356Phase 2
- A Study of SGT-53 in Children With Refractory or Recurrent Solid TumorsSuspendedNCT02354547Phase 1
- Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant DiseasesCompletedNCT02349906Phase 2
- NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First RelapseWithdrawnNCT02348255Phase 2
- A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma MultiformeActive, not recruitingNCT02344355Phase 2
- HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnNCT02343666Phase 1
- Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin LymphomaCompletedNCT02342782Phase 1
- Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02337426Phase 1
- Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid MalignanciesStatus unknownNCT02333838Phase 2
- A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 MutationStatus unknownNCT02333513Not applicable
- Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantSuspendedNCT02333162Phase 1
- Treosulfan-based Conditioning in Paediatric Patients With Haematological MalignanciesCompletedNCT02333058Phase 2
- A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First RelapseCompletedNCT02330991Phase 2
- A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCLTerminatedNCT02323230Phase 2
- CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding PatientsStatus unknownNCT02320383Phase 2
- Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple MyelomaWithdrawnNCT02315157Phase 1
- Maintenance Treatment Versus Observation in Elderly Patients With PCNS LymphomaStatus unknownNCT02313389Phase 3
- Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder CancerCompletedNCT02311101Phase 1
- Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)TerminatedNCT02310997Phase 2
- Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in ChildrenCompletedNCT02308527Phase 2
- Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC PatientsCompletedNCT02307487Phase 2
- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)Active, not recruitingNCT02305654Phase 3
- Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory NeuroblastomaActive, not recruitingNCT02298348Phase 1
- GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory LymphomaTerminatedNCT02295722Phase 1/2
- Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCTCompletedNCT02294552Phase 2
- Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic StrictureStatus unknownNCT02287389Not applicable
- Low Dose Metronomic Poly-chemotherapy for Metastatic CRCCompletedNCT02280694Phase 2
- Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02278887Phase 3
- HER2-Peptide Vaccination of Patients With Solid TumorsCompletedNCT02276300Phase 1
- Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin LymphomaStatus unknownNCT02275598Phase 2
- Infusion of Allogeneic, 3rd Party CD19-specific T CellsWithdrawnNCT02274506Phase 1
- Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal CancerCompletedNCT02271464Phase 2
- MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) ProphylaxisStatus unknownNCT02270307Phase 2/3
- Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade GliomasCompletedNCT02263105Phase 2
- Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)CompletedNCT02248012Phase 2
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple MyelomaCompletedNCT02237261Phase 2
- Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT02227901Phase 1
- Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaCompletedNCT02219737Phase 1
- Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaCompletedNCT02217163Phase 2
- Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast CancerWithdrawnNCT02215876Phase 2
- A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade GliomasStatus unknownNCT02209428Phase 2
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02204241Phase 1/2
- Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.CompletedNCT02203643Phase 2
- Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial NeoplasiaCompletedNCT02199327Phase 4
- Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT02194374Phase 1
- Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02187133Phase 1
- Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast CancerTerminatedNCT02183805Phase 2
- Intra-Osseous Co-Transplant of UCB and hMSCCompletedNCT02181478Early Phase 1
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk NeuroblastomaActive, not recruitingNCT02176967Phase 3
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02176213Phase 2
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor SourceCompletedNCT02167958Phase 1
- A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer PatientsCompletedNCT02162888Phase 1
- Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell TumorsCompletedNCT02161692Phase 2